BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8894262)

  • 1. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker.
    Rosenthal J; Bahrmann H; Benkert K; Baumgart P; Bönner G; Klein G; Neiss A; Schnelle K; Frohlich ED
    Cardiology; 1996; 87(5):409-14. PubMed ID: 8894262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group.
    Ostman J; Asplund K; Bystedt T; Dahlöf B; Jern S; Kjellström T; Lithell H
    J Intern Med; 1998 Aug; 244(2):95-107. PubMed ID: 10095796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinapril: a double-blind, placebo-controlled trial in essential hypertension.
    Maclean D
    Angiology; 1989 Apr; 40(4 Pt 2):370-81. PubMed ID: 2650581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
    Larochelle P; Haynes B; Maron N; Dugas S
    Clin Ther; 1994; 16(5):838-53. PubMed ID: 7859244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.
    Hausberg M; Barenbrock M; Hohage H; Müller S; Heidenreich S; Rahn KH
    Hypertension; 1999 Mar; 33(3):862-8. PubMed ID: 10082500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety profile of quinapril: is there a difference among ACE inhibitors?
    Canter D; Frank GJ; Knapp LE; McLain RW
    Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII39-42. PubMed ID: 2189620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril.
    Frishman WH; Greenberg S
    Am J Hypertens; 1991 Oct; 4(10 Pt 1):827-31. PubMed ID: 1747216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril.
    Materson BJ
    Am J Cardiol; 1992 Apr; 69(10):46C-53C. PubMed ID: 1546639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinapril versus atenolol in the treatment of mild to moderate essential hypertension.
    Bahena JH; Estrella ME; Muñoz M
    Clin Ther; 1992; 14(4):527-36. PubMed ID: 1525787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall tolerance and safety of quinapril in clinical trials.
    Frank GJ; Knapp LE; McLain RW
    Angiology; 1989 Apr; 40(4 Pt 2):405-15. PubMed ID: 2650583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and tolerability of quinapril.
    Knapp LE; Frank GJ; McLain R; Rieger MM; Posvar E; Singer R
    J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S47-55. PubMed ID: 1691407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.
    Culy CR; Jarvis B
    Drugs; 2002; 62(2):339-85. PubMed ID: 11817979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Conversion from oral ACE inhibitor to intravenous quinaprilat administration in mild to moderate essential hypertension].
    Schmidt BM; Smilde J; Oldenbroek C; Wehling M
    Med Klin (Munich); 1998 Dec; 93(12):701-6. PubMed ID: 10024837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of hypertension in older patients.
    Schnaper HW
    J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S56-61. PubMed ID: 1691408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
    Sedman AJ; Posvar E
    Angiology; 1989 Apr; 40(4 Pt 2):360-9. PubMed ID: 2539762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group.
    Flack JM; Yunis C; Preisser J; Holmes CB; Mensah G; McLean B; Saunders E
    Arch Intern Med; 2000 Jun; 160(12):1842-7. PubMed ID: 10871979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Study Group of Quinapril in Arterial Hypertension. The Steering Committee].
    Ambrosioni E; Brusca A; Caponnetto S; Condorelli M; Corea L; Dal Palù C; Fogari R; Mameli P; Mancia G; Neri Serneri GG
    Minerva Cardioangiol; 1992 Mar; 40(3):85-96. PubMed ID: 1630680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy and safety of quinapril with that of enalapril in the treatment of mild to moderate essential hypertension.
    Taylor SH
    Angiology; 1989 Apr; 40(4 Pt 2):382-8. PubMed ID: 2539763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of quinapril in the elderly patient.
    Schnaper HW
    Am J Hypertens; 1990 Nov; 3(11):278S-282S. PubMed ID: 2261146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.